← Latest briefing

Health

Early trial of daraxonrasib with chemotherapy stops tumour growth in pancreatic cancer

Cancer became undetectable on scans in one in 12 patients, though a comparison with chemotherapy alone is still missing.

The short version

  • Early trials gave daraxonrasib with chemotherapy to patients with advanced pancreatic cancer that had spread, and cancer became undetectable on scans in one in 12 patients.[BBC News]
  • Tumours stopped growing in almost all of the 61 recently diagnosed participants, and the trial followed patients for about a year and a half on average.[BBC News]
  • Cancer Research UK called the results the biggest leap forward in decades, while Dr Wungki Park said early response and disease control gains were encouraging.[BBC News]
  • Without a comparison group receiving chemotherapy alone, doctors cannot yet confirm the benefit or any gain in overall survival; Revolution Medicines funded the trial.[Fox News]

Key facts

  • Cancer became undetectable on scans in one in 12 patients given daraxonrasib with chemotherapy in early medical trials.[BBC News]
  • Tumours stopped growing in almost all of the 61 recently diagnosed participants, who had advanced pancreatic cancer that had spread.[BBC News]
  • Daraxonrasib is a KRAS inhibitor that has already been approved in the US.[BBC News]
  • Patients were followed for about a year and a half on average, and some did not see their cancer return during that time.[BBC News]
  • A year after starting treatment, 76.6% of patients were alive, compared with 40-45% of patients given chemotherapy alone.[The Guardian]
  • Without a direct comparison group receiving chemotherapy alone, doctors cannot yet confirm how much better the regimen performs or whether it definitively extends overall survival.[Fox News]
  • The trial was funded by Revolution Medicines, the California-based developer of daraxonrasib.[Fox News]

What remains uncertain

  • Benefit on overall survival remains unconfirmed because the trial had no control group receiving chemotherapy alone.[Fox News]
  • The 76.6% one-year survival figure is compared with typical chemotherapy-alone outcomes rather than a concurrent control group.[The Guardian · Fox News]

Sources

Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.